PTPN11 and lung cancer: SHP2 mutants undergo LLPS in the cytoplasm of cancer cells, enhancing MEK1/2 and ERK1/2 phosphorylation levels, and activating MAPK pathway, leading to increased proliferation, survival, and metastasis of lung cancer cells.